Vesicular stomatitis virus encoding ebola virus glycoprotein
As of the edition of 20 October 2026, Vesicular stomatitis virus encoding ebola virus glycoprotein is a vaccine component: marketed, first approved in 2019 (US); US protection ends in 2031.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2019
- Kind
- Vaccine component
- Brand name
- Ervebo
- First approved
- 19 December 2019 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Merck & Co.
- Registered trials
- 7, 1 stopped early
- Disease areas
- Infections; Lungs and airways
US protection
US protection ends in 2031.
The reference-product exclusivity ends in 2031. The application that gives this date is held by Merck & Co..
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 0 | 2 | 0 |
| Phase 3 | 2 | 0 | 1 | 1 |
| Phase 4 | 2 | 0 | 1 | 0 |
| All trials | 7 |